Renalytix plc
Company Profile
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States. Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting approximately 15 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.
Latest Company Summary
Investor Access
There is no Investor Access event planned at the moment - click on "Register your Interest" and we'll tell the Company that you'd like to attend one in the future and update you when an event is planned.
| Event | Date |
| Year End | 30 June |
| Half Year End | 31 December |
| Preliminary Results* | October |
| Interim Results* | March |
| AGM* | December |
* Months based on previous announcements of this kind
